CD22 and systemic mastocytosis: Overall, our results confirm and extend on previous observations [24,25,73] regarding the existence of variable patterns of expression on BMMC from SM patients for all individual markers evaluated (i.e., CD22, CD25, CD30, CD33, CD123, and FcεRI).